| AJTR Copyright © 2009-All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711 |
Am J Transl Res 2009;1(2):101-114
Review Article
Insulin-like growth factor-1 receptor-targeted therapy for non-small
cell lung cancer: a mini review
Ming Yin, Xiaoxiang Guan, Zhongxin Liao, Qingyi Wei
Departments of Epidemiology and Radiation Oncology, The University of Texas M. D. Anderson Cancer Center,
1515 Holcombe Blvd, Houston, TX 77030, USA
Received January 24, 2009; accepted January, 2009; available online January, 2009
Abstract: Lung cancer leads all other cancers in both incidence and mortality. Recent advances in underlying
molecular pathogenesis have validated a panel of protein tyrosine kinases as new targets in lung cancer
treatment. Insulin-like growth factor-1 receptor (IGF-1R) is an important tyrosine kinase receptor involved in cell
proliferation, differentiation, metabolism, apoptosis, and angiogenesis. Aberrant activation of IGF-1R is frequently
found in patients with lung cancer and contributes to malignant transformation and poor prognosis for patients
with lung cancer. In this review, we focused on recent progress in the research of IGF-1R’s role in lung cancer
development and progression, including its structure and biological function, potential mechanisms of aberrant
activation, and related oncogenic effects. We also discussed effective IGF-1R antagonists that are currently
registered for clinic trials or are undergoing preclinical study with special emphasis on their antibodies and small
molecule tyrosine kinase inhibitors. (AJTR901008).
Key Words: Insulin-like growth factor, Lung cancer, Receptor, Targeted therapy
Full Text PDF
Address all correspondence to:
Qingyi Wei, MD, PhD
Department of Epidemiology
The University of Texas, M. D. Anderson Cancer Center
1515 Holcombe Blvd, Unit 1365
Houston, TX 77030, USA
Tel: 1 713 792 3020
Fax: 1 713 563 0999
E-mail: qwei@mdanderson.org
Review Article
Insulin-like growth factor-1 receptor-targeted therapy for non-small
cell lung cancer: a mini review
Ming Yin, Xiaoxiang Guan, Zhongxin Liao, Qingyi Wei
Departments of Epidemiology and Radiation Oncology, The University of Texas M. D. Anderson Cancer Center,
1515 Holcombe Blvd, Houston, TX 77030, USA
Received January 24, 2009; accepted January, 2009; available online January, 2009
Abstract: Lung cancer leads all other cancers in both incidence and mortality. Recent advances in underlying
molecular pathogenesis have validated a panel of protein tyrosine kinases as new targets in lung cancer
treatment. Insulin-like growth factor-1 receptor (IGF-1R) is an important tyrosine kinase receptor involved in cell
proliferation, differentiation, metabolism, apoptosis, and angiogenesis. Aberrant activation of IGF-1R is frequently
found in patients with lung cancer and contributes to malignant transformation and poor prognosis for patients
with lung cancer. In this review, we focused on recent progress in the research of IGF-1R’s role in lung cancer
development and progression, including its structure and biological function, potential mechanisms of aberrant
activation, and related oncogenic effects. We also discussed effective IGF-1R antagonists that are currently
registered for clinic trials or are undergoing preclinical study with special emphasis on their antibodies and small
molecule tyrosine kinase inhibitors. (AJTR901008).
Key Words: Insulin-like growth factor, Lung cancer, Receptor, Targeted therapy
Full Text PDF
Address all correspondence to:
Qingyi Wei, MD, PhD
Department of Epidemiology
The University of Texas, M. D. Anderson Cancer Center
1515 Holcombe Blvd, Unit 1365
Houston, TX 77030, USA
Tel: 1 713 792 3020
Fax: 1 713 563 0999
E-mail: qwei@mdanderson.org
 | |  | |  | |  | |  | |  | |  | |  |